Opthea Ltd-spon Adr (OPT)

$4.99

Live

Performance

  • $4.94
    $5.12
    $4.99
    downward going graph

    1.0%

    Downside

    Day's Volatility :3.56%

    Upside

    2.59%

    downward going graph
  • $1.60
    $5.45
    $4.99
    downward going graph

    67.94%

    Downside

    52 Weeks Volatility :70.64%

    Upside

    8.44%

    downward going graph

Returns

PeriodOpthea Ltd-spon AdrSector (Health Care)Index (Russel 2000)
3 Months
138.76%
3.6%
0.0%
6 Months
47.63%
10.2%
0.0%
1 Year
197.02%
19.6%
0.0%
3 Years
-32.11%
16.8%
-23.0%

Highlights

Market Capitalization
773.9M
Book Value
-$0.07
Earnings Per Share (EPS)
-2.76
Wall Street Target Price
14.32
Profit Margin
0.0%
Operating Margin TTM
-164535.56%
Return On Assets TTM
-83.43%
Return On Equity TTM
-3383.08%
Revenue TTM
261.9K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-68.30000000000001%
Gross Profit TTM
218.4K
EBITDA
-191.8M
Diluted Eps TTM
-2.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-12.19
EPS Estimate Next Year
-10.67
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    11%Buy
    33%Hold
    55%Sell
Based on 9 Wall street analysts offering stock ratings for Opthea Ltd-spon Adr(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
2
Hold
3
2
2
Sell
5
6
6

Analyst Forecast

What analysts predicted

Upside of 186.97%

Current $4.99
Target $14.32

Company Financials

FY19Y/Y Change
Revenue
78.2K
-
Net Income
-10.4M
↑ 20.44%
Net Profit Margin
-13.3K%
-
FY20Y/Y Change
Revenue
40.7K
↓ 47.5%
Net Income
-7.6M
↓ 25.9%
Net Profit Margin
-18.8K%
↓ 5468.89%
FY21Y/Y Change
Revenue
52.4K
↑ 16.17%
Net Income
-34.6M
↑ 309.22%
Net Profit Margin
-66.1K%
↓ 47325.73%
FY22Y/Y Change
Revenue
63.7K
↑ 32.17%
Net Income
-65.2M
↑ 104.69%
Net Profit Margin
-102.4K%
↓ 36266.34%
FY23Y/Y Change
Revenue
72.8K
↑ 19.54%
Net Income
-95.7M
↑ 53.55%
Net Profit Margin
-131.5K%
↓ 29116.08%
FY24Y/Y Change
Revenue
125.1K
↑ 15.42%
Net Income
-221.0M
↑ 55.1%
Net Profit Margin
-176.7K%
↓ 45197.39%
Q3 FY22Q/Q Change
Revenue
154.1K
↑ 237.59%
Net Income
-60.3M
↑ 9.38%
Net Profit Margin
-39.1K%
↑ 81627.49%
Q4 FY22Q/Q Change
Revenue
52.0K
↓ 66.22%
Net Income
-77.0M
↑ 27.75%
Net Profit Margin
-148.0K%
↓ 108840.77%
Q1 FY23Q/Q Change
Revenue
140.8K
↑ 170.49%
Net Income
-48.9M
↓ 36.45%
Net Profit Margin
-34.8K%
↑ 113203.35%
Q2 FY23Q/Q Change
Revenue
55.9K
↓ 60.31%
Net Income
-64.9M
↑ 32.69%
Net Profit Margin
-116.2K%
↓ 81445.13%
Q4 FY23Q/Q Change
Revenue
61.3K
↑ 9.67%
Net Income
-96.9M
↑ 49.31%
Net Profit Margin
-158.2K%
↓ 41999.42%
Q2 FY24Q/Q Change
Revenue
59.6K
↓ 2.69%
Net Income
-124.1M
↑ 27.97%
Net Profit Margin
-208.1K%
↓ 49856.26%
FY19Y/Y Change
Total Assets
12.8M
↓ 45.38%
Total Liabilities
2.2M
↓ 44.7%
FY20Y/Y Change
Total Assets
23.6M
↑ 85.3%
Total Liabilities
2.3M
↑ 5.06%
FY21Y/Y Change
Total Assets
105.7M
↑ 304.06%
Total Liabilities
2.4M
↓ 7.4%
FY22Y/Y Change
Total Assets
42.2M
↓ 56.62%
Total Liabilities
8.5M
↑ 286.43%
FY23Y/Y Change
Total Assets
66.3M
↑ 64.27%
Total Liabilities
70.2M
↑ 765.76%
FY24Y/Y Change
Total Assets
188.8M
↑ 91.39%
Total Liabilities
264.6M
↑ 153.22%
Q3 FY22Q/Q Change
Total Assets
240.8M
↑ 301.01%
Total Liabilities
152.5M
↑ 1163.54%
Q4 FY22Q/Q Change
Total Assets
103.9M
↓ 36.04%
Total Liabilities
65.8M
↓ 36.04%
Q1 FY23Q/Q Change
Total Assets
147.5M
↓ 4.2%
Total Liabilities
156.3M
↑ 60.24%
Q2 FY23Q/Q Change
Total Assets
66.3M
↓ 33.15%
Total Liabilities
70.2M
↓ 33.15%
Q4 FY23Q/Q Change
Total Assets
166.5M
↑ 68.79%
Total Liabilities
213.4M
↑ 104.24%
Q2 FY24Q/Q Change
Total Assets
188.8M
↑ 13.39%
Total Liabilities
264.6M
↑ 23.98%
FY19Y/Y Change
Operating Cash Flow
-8.3M
↓ 40.25%
Investing Cash Flow
223.0K
↓ 1032.61%
Financing Cash Flow
4.3M
↑ 1431.36%
FY20Y/Y Change
Operating Cash Flow
-3.9M
↓ 52.24%
Investing Cash Flow
328.2K
↑ 48.22%
Financing Cash Flow
23.2M
↑ 444.31%
FY21Y/Y Change
Operating Cash Flow
-34.8M
↑ 700.51%
Investing Cash Flow
501.4K
↑ 37.99%
Financing Cash Flow
89.3M
↑ 247.45%
FY22Y/Y Change
Operating Cash Flow
-50.1M
↑ 56.62%
Investing Cash Flow
-11.9K
↓ 102.58%
Financing Cash Flow
120.6K
↓ 99.85%
FY23Y/Y Change
Operating Cash Flow
-81.0M
↑ 69.07%
Investing Cash Flow
-14.7K
↑ 29.83%
Financing Cash Flow
112.4M
↑ 97387.2%
Q3 FY22Q/Q Change
Operating Cash Flow
-54.2M
↓ 12.18%
Investing Cash Flow
-3.5K
↓ 53.99%
Financing Cash Flow
130.7M
↓ 226477.28%
Q4 FY22Q/Q Change
Operating Cash Flow
-69.2M
↑ 27.75%
Investing Cash Flow
-3.5K
↑ 0.0%
Financing Cash Flow
167.0M
↑ 27.75%
Q1 FY23Q/Q Change
Operating Cash Flow
-38.4M
↓ 44.53%
Investing Cash Flow
-7.5K
↑ 112.74%
Financing Cash Flow
67.3K
↓ 99.96%
Q2 FY23Q/Q Change
Operating Cash Flow
-50.5M
↑ 31.55%
Investing Cash Flow
-7.5K
↑ 0.0%
Financing Cash Flow
-965.9K
↓ 1534.29%

Technicals Summary

Sell

Neutral

Buy

Opthea Ltd-spon Adr is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Opthea Ltd-spon Adr
Opthea Ltd-spon Adr
27.95%
47.63%
197.02%
-32.11%
-59.43%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Opthea Ltd-spon Adr
Opthea Ltd-spon Adr
NA
NA
NA
-12.19
-33.83
-0.83
NA
-0.07
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Opthea Ltd-spon Adr
Opthea Ltd-spon Adr
Sell
$773.9M
-59.43%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Opthea Ltd-spon Adr

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 61.27K → 59.62K (in $), with an average decrease of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -48.92M → -124.05M (in $), with an average decrease of 36.7% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 76.9%

Institutional Holdings

  • VGI PARTNERS PTY Ltd

    1.89%

  • Baker Bros Advisors LP

    1.41%

  • Victory Capital Management Inc.

    0.55%

  • Teacher Retirement System Of Texas

    0.18%

  • Millennium Management LLC

    0.05%

  • BMO Capital Markets Corp.

    0.03%

Company Information

opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea's lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com

Organization
Opthea Ltd-spon Adr
Employees
33
CEO
Dr. Frederic Guerard M.S., Pharm.D.
Industry
Health Technology

Discover More

FAQs